19 May 2013
Keywords: b-ms, orencia, almost, doubles, ra, remission, usa
Article | 03 November 2008
The USA's Bristol-Myers Squibb presented strong results from a Phase IIIb study of its Orencia (abatacept) in the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 November 2008
1 December 2008
17 May 2013
© 2013 thepharmaletter.com